Peptide handling
FOXO4-DRI reconstitution calculator
Reconstitution calculator for FOXO4-DRI, prefilled for its 5 and 10 mg vials. Get the concentration, the dose volume and the U-100 syringe reading.
Start from a compound
Fills the vial size and a starting water volume. Only compounds with a citable range fill a dose.
The second is the question asked once the syringe is already filled, or when checking a vial someone else reconstituted.
1 mg = 1,000 mcg. Published figures are usually micrograms; vial labels are milligrams.
- Draw to
- 10 unitson a U-100 syringe
- Dose
- 250 mcg
- Dose volume
- 0.1 mL
- Concentration
- 2.5 mg/mL
- Per unit
- 25 mcg
- Doses per vial
- 20whole doses; a partial one is not counted
Shown on a 30-unit (0.3 mL) U-100 syringe, the smallest that holds this draw.
FOXO4-DRI — Animal data only — no human dosing study
Extrapolated from animal studies. No human dosing study exists for this compound, so this range is an inference, not a finding. The prefilled dose is the low end of that range, daily, escalated across a 16-week schedule.
Vial size and water volume are a starting point for the arithmetic, not a recommendation.
Adding more water makes the same dose a larger, easier-to-read mark on the syringe. It does not change how many doses the vial holds.
Vial sizes and starting volume
FOXO4-DRI is commonly supplied in 5 mg and 10 mg vials. The calculator opens on a 5 mg vial with 2 mL of bacteriostatic water — a starting point for the arithmetic, not a recommendation. Change either and everything recalculates.
That combination gives 2.5 mg/mL, so one insulin unit holds 25 mcg and a 250 mcg dose is 10 units.
What dose to enter
A range of 250–500 mcg per dose can be cited for FOXO4-DRI, daily, escalated across a 16-week schedule. The dose field opens at the low end of it.
Animal data only — no human dosing study
Extrapolated from animal studies. No human dosing study exists for this compound, so this range is an inference, not a finding.
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. — Preclinical mouse study. Foundational mouse study on senescent-cell clearance; establishes the mechanism, not a human dose.
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. — Structural/mechanistic study. Describes the FOXO4-p53 binding mechanism the peptide disrupts; no dosing data.
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. — In vitro human cell study. In vitro work on human chondrocytes; establishes cellular activity, not an in-vivo human dose.
- FOXO4-DRI regulates endothelial cell senescence via the p53 signaling pathway. — Preclinical cell study. Further mechanistic work on endothelial senescence; no dosing data.
- ClinicalTrials.gov registry — FOXO4-DRI search (no registered human trials as of June 2026). — ClinicalTrials.gov registry. Confirms no human trial is registered, which is why no human dosing study exists to cite.
Related
- FOXO4-DRI — the product page, with its current batch.
- Bacteriostatic water — what goes in the vial.
- Peptide reconstitution calculator — the general version, with the blend and half-life calculators alongside it.
- Dosing reference — published schedules, each with the evidence behind it.
For research use only. This tool performs arithmetic on figures you supply — it is not medical guidance and does not recommend a dose for any compound.